A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COMBINATION WITH PACLITAXEL CARBOPLATIN AND BEVACIZUMAB FOR PATIENTS WITH NEWLY DIAGNOSED STAGE III/IV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Peritoneal Primary Carcinoma
    Fallopian Tube Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1. Receive a histologic diagnosis of epithelial ovarian, peritoneal primary, or fallopian tube cancers 2. Age = 18 years 3. For women of childbearing potential: agreement to remain abstinent

You may not be eligible for this study if the following are true:

  • 1. Received a current diagnosis of borderline epithelial ovarian tumor 2. Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer 3. Received prior chemotherapy for any abdominal or pelvic tumor that includes NACT for ovarian, primary peritoneal or fallopian tube cancer


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.